Table 6.
Summary of other FDA-approved anticancer therapies investigated in current study by category and subcategory
| Drug category | Drug name | Indicated for breast cancer | Labeled indications if not indicated for breast cancer (ICD-9-CM codes) | Initial FDA approval during study period |
|---|---|---|---|---|
| Hormone therapies | Anastrozole | Yes | 1995 | |
| Exemestane | Yes | 1999 | ||
| Fluoxymesterone | Yes | 1956 | ||
| Fulvestrant | Yes | April 2002 | ||
| Goserelin | Yes | 1989 | ||
| Letrozole | Yes | 1997 | ||
| Leuprolide | No | 185 | 1985 | |
| Tamoxifen | Yes | 1977 | ||
| Targeted therapies | Bortezomib | No | May 2003 | |
| Erlotinib | No | November 2004 | ||
| Imatinib | No | 150-154, 158.0, 159.0, 159.8, 159.9, 171.5-171.9, 205.1, 205.9, 238.1, 239 | May 2001 | |
| Sorafenib | No | 155.0, 155.2, 197.7, 189.0, 189.8, 189.9, 198.0 | December 2005 | |
| Immunotherapies | Aldesleukin | No | 172, 189.0, 189.1, 189.8, 189.9, 198.0, 198.2 | 1992 |
| Alemtuzumab | No | 204.1, 204.9 | May 2001 | |
| Bevacizumab | Yes1 | 153, 154, 162.2-162.5, 162.8, 162.9, 191, 197.0, 197.5, 198.3 | February 20042 | |
| Cetuximab | No | 140-149, 153, 154, 160, 161, 173.0-173.4, 195.0, 197.5 | February 2004 | |
| Denileukin diftitox | No | 202.1, 202.2 | 1999 | |
| Gemtuzumab ozogamicin | No | 205.0, 205.9 | 2000 | |
| Panitumumab | No | 153, 154, 197.5 | September 2006 | |
| Rituximab3 | No | 200, 202, 204.1, 204.9, 714 | 1997 | |
| Thalidomide | No | 0.17.1, 695.2, 203.0 | 1998 | |
| Trastuzumab | Yes | 1998 |
1Breast cancer indication approved by FDA on February 22, 2008 and revoked in November 2011.
2Colorectal cancer indication approved in February 2004, Non-small cell lung carcinoma in October 2006, Glioblastoma in May 2009.
3Obtained FDA approval for Wegener’s Granulomatosis (WG) and Microscopic Polyngiitis (MPA) only in April 2011 (post-study period).